BLNK and breast cancer: The compound 3F1 demonstrated significant growth inhibition of BCA, BCSC-P, and BCSC, and IC50 doses against these breast cancer cells were found to be less than the IC50 dose for H9c2 normal cardiomyoblasts too (Table 1).